Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594594 | 0.78 | ALDH1A1 (0.53) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL14142241 | 0.78 | ALDH1A1 (0.44) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL3378773 | 0.78 | CA1 (0.39) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL2143927 | 0.78 | CA1 (0.42) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL7355054 | 0.78 | CA1 (0.39) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL28993182 | 0.78 | CA1 (0.39) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL25265218 | 0.77 | TDP1 (0.36) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL6760798 | 0.77 | CYP2C19 (0.38) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL411850 | 0.77 | CA1 (0.36) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL1793776 | 0.76 | CA1 (0.38) | CA1CA2CA9ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | claimed |
| EP-0912571-B1 | NAPHTHYRIDINES WHICH AFFECT IL-4 AND G-CSF | SCHERING CORP (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6723860-B2 | 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1207162-B1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1207162-A1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | Ube Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-5942522-A | 1-BENZYL-3-ETHOXYCARBONYL-4-DIMETHYLAMINOETHOXY-6-METHYL-2-(1H) -QUINOLINONE; ANTIVIRAL AGAINST DNA CONTAINING VIRUSES, SUCH AS HERPES GROUP VIRUSES | SCHERING CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| US-5939431-A | Naphthyridines which affect IL-4 and G-CSF | SCHERING CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0912571-A2 | NAPHTHYRIDINES WHICH AFFECT IL-4 AND G-CSF | SCHERING CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048368-A2 | NAPHTHYRIDINES WHICH AFFECT IL-4 AND G-CSF | SCHERING CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| EP-0580812-A1 | ANTI-TUMOR AND ANTI-PSORIATIC AGENTS | SCHERING CORPORATION (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0549729-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5190956-A | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections | SCHERING CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5179107-A | Herpes | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| US-5175151-A | Useful for treating herpes group viruses | SCHERING CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1992018507-A1 | ANTI-TUMOR AND ANTI-PSORIATIC AGENTS | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0508792-A1 | Anti-tumor and anti-psoriatic agents | SCHERING CORPORATION (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004327-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | ACSL1, ACSL4, ACSL3 | CA1 1373/4885CA2 2720/4885CA9 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.